Clinical Trial Update: Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating alisertib, with or without fulvestrant, in locally advanced or metastatic endocrine-resistant breast cancer has completed and posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Alisertib (alisertib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Mayo Clinic | Conditions: Estrogen Receptor Status, HER2/Neu Negative | Phase 2 | Status: COMPLETED | Results posted: 2024-10-18